ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression (DEMPROG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01642420
Recruitment Status : Unknown
Verified September 2012 by Malene Schjønning Nielsen, Zealand University Hospital.
Recruitment status was:  Recruiting
First Posted : July 17, 2012
Last Update Posted : September 13, 2012
Sponsor:
Collaborator:
Rigshospitalet, Denmark
Information provided by (Responsible Party):
Malene Schjønning Nielsen, Zealand University Hospital

Brief Summary:

Alzheimers disease (AD) is the most common course of cognitive decline and thereby the course of more than half of all cases of dementia. A proper AD diagnosis is rested on a number of examinations and tests, which combined can make AD diagnosis likely. But no single test or examination can unambiguous determine whether the patient has AD or not. Comparatively no examination or test can with accuracy predict whether a healthy person or a person with only mild cognitive (MCI)impairment in time will evolve AD.

Quantitative Electroencephalography (qEEG), cerebrospinal fluid (CSF) biomarkers, linear CT analyses and Timed Up and Go - Dual Task (TUG-DT) are relatively inexpensive and and widely available diagnostic methods, which have the potential to diagnose AD at an early stage in a reliable accurate way. But they also have the potential to predict which patients diagnosed with MCI have particular risk of developing dementia.

The purpose of the study is to investigate the relations between qEEG, CSF biomarkers, CT analyses and TUG-DT outcome and clinical features in healthy persons as well as patients with MCI and AD Furthermore to investigate whether qEEG or CSF biomarkers can predict which patients with MCI will in time evolve AD.


Condition or disease
Alzheimers Disease Mild Cognitive Impairment

Study Type : Observational
Estimated Enrollment : 115 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Quantitative Electroencephalography, Cerebrospinal Fluid Biomarkers, Linear CT Analyses and Timed Up and GO Dual Task as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression.
Study Start Date : April 2012
Estimated Primary Completion Date : February 2017
Estimated Study Completion Date : February 2017


Group/Cohort
Mild cognitive impairment
Patients diagnosed with mild cognitive impairment
Alzheimers disease
Patients diagnosed with mild Alzheimers disease
Healthy control persons
Age matched healthy persons



Primary Outcome Measures :
  1. Conversion from Mild Cognitive Impairment to Alzheimers disease [ Time Frame: Every year in totally of 3 years ]
    The primary outcome measure is progression of clinical symptoms to an extent where the formal NINCDS-ADRDA criteria for dementia is meet. The progression is based upon clinical symptoms as well as explorative determinants in form of clinical tests, CSF analysis and qEEG analysis.


Biospecimen Retention:   Samples Without DNA
Cerebrospinalfluid (CSF) CSF is analysed to find Alzheimer Disease biomarkers


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with MCI and AD will be recruitted among consectutively refered patients in a memory clinic. Participation is voluntary Healthy control persons will be recuitted by posters and notices
Criteria

Inclusion Criteria:

For patients:

  • age 50 to 90
  • diagnosed with MCI or AD
  • cerebrospinal fluid examination and EEG performed at baseline

For control persons:

  • age 50 to 90
  • MMSE score equal or above 26
  • ACE score equal or above 85
  • Normal physical examination, including normal blood samples, CT of cerebrum and EEG examination

Exclusion Criteria:

  • Pregnant or breastfeeding
  • psychiatric disease, former depression is allowed if antidepressive treatment has been initiated of a leat 3 months duration
  • Neurologic or somatic disease, including former severe head trauma or neuroinfection
  • Antipsychotic treatment
  • Former severe abuse of alcohol, medication or drugs
  • ECT treatment or anaesthesia within the last 3 months
  • no closely related person to assist the patient

Additionally exclusion criteria for healthy control persons:

  • meet the diagnostic criteria for MCI or AD

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01642420


Contacts
Contact: Malene s Nielsen, MD 0045 2868 0034 malni@regionsjaelland.dk
Contact: Peter Høgh, MD, Ph.D 0045 4732 2809 phh@regionsjaelland.dk

Locations
Denmark
Neurologisk Afd, Roskilde Sygehus Recruiting
Roskilde, Denmark, 4000
Principal Investigator: Malene S Nielsen, MD         
Sponsors and Collaborators
Zealand University Hospital
Rigshospitalet, Denmark
Investigators
Principal Investigator: Malene S Nielsen, MD Roskilde Hospital, Department of Neurology

Responsible Party: Malene Schjønning Nielsen, MD, PhD student, Zealand University Hospital
ClinicalTrials.gov Identifier: NCT01642420     History of Changes
Other Study ID Numbers: DEMPROG 2012
First Posted: July 17, 2012    Key Record Dates
Last Update Posted: September 13, 2012
Last Verified: September 2012

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Cognitive Dysfunction
Disease Progression
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders
Disease Attributes
Pathologic Processes